Axonal damage revealed by accumulation of β-APP in HIV-positive individuals without AIDS

Journal of Neuropathology and Experimental Neurology

Volumn 56, Issue 11, 1997, Pages 1262-1268

  An, Shu F ^a   Giometto, Bruno ^b   Groves, Mike ^a   Miller, Robert F ^c   Beckett, Andrew A J ^a   Gray, Françoise ^d   Tavolato, Bruno ^e   Scaravilli, Francesco ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PADOVA   (Italy)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d HENRI MONDOR HOSPITAL   (France)

^e NONE

Author keywords

Axonal changes; HIV positive asymptomatic patients; Immune activation; Neuropsychological disorder; Polymerase chain reaction (PCR); Reversible; APP

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CYTOKINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FRONTAL LOBE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; NERVE LESION; NEUROPATHOLOGY; PRIORITY JOURNAL; WHITE MATTER;

EID: 0030730883     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199711000-00011     Document Type: Article

References (55)

1. Harrison MJU, McArthur JC. AIDS-associated dementia. In "AIDS and neurology." London: Churchill Livingstone; 1995:31-64
2. Scaravilli F, Gray F, Mikol J, Sinclair E. Pathology of the central nervous system. In: Scaravilli F, ed. The neuropathology of HIV infection. Springer Verlag; 1993:99-170
3. Ho DD, Rota TR, Schooley RT, et al. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurological syndrome related to the acquired immunodeficiency syndrome. N Engl J Med 1985;313:1493-97
4. An SF, Ciardi A, Giometto B, et al. Investigation on the expression of major histocompatibility complex class II and cytokines and detection of HIV-1 DNA within brains of asymptomatic and symptomatic HIV-1-positive patients. Acta Neuropathol 1996;91:494-503
5. Grant I, Atkinson JH, Hesselink JR, et al. Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Ann Intern Med 1987;107(6):828-36
6. Karlsen NR, Reinvang I, Froland SS. Slowed reaction time in asymptomatic HIV-positive patients. Acta Neurol Scand 1992; 86(3): 242-46
7. Bornstein RA, Nasrallah HA, Para MF, Whitacre CC, Pass RJ. Change in neuropsychological performance in asymptomatic HIV infection: 1-year follow-up. AIDS 1993;7(12):1607-11
8. Nuwer MR, Miller EN, Visscher BR, et al. Asymptomatic HIV infection does not cause EEG abnormalities: Results from the Multicenter AIDS Cohort Study (MACS). Neurology 1992;42:1214-19
9. Newton TF, Leuchter AF, Miller EN, Weiner H. Quantitative EEG in patients with AIDS and asymptomatic HIV infection. Clin Electroencephalogr 1994;25:18-25
10. Wilkinson ID, Miller RF, Miszkiel KA, et al. Cerebral proton magnetic resonance spectroscopy in asymptomatic HIV infection. AIDS 1997;11:289-95
11. Gray F, Lescs MC, Keohane C, et al. Early brain changes in HIV infection: Neuropathological study of 11 HIV seropositive, non-AIDS cases. J Neuropathol Exp Neurol 1992;51:177-85
12. An SF, Giometto B, Scaravilli T, et al. Programmed cell death in brains of HIV-1-positive AIDS and pre-AIDS patients. Acta Neuropathol 1996;91:169-73
13. Price RW, Sidtis JJ, Brew BJ. AIDS demetia complex and HIV-1 infection: A view from the clinic. Brain Pathol 1991;1:155-62
14. Sherriff FE, Bridges LR, Sivaloganathan S. Early detection of axonal injury after human head trauma using immunocytochemistry for β-amyloid precursor protein. Acta Neuropathol 1994;87:55-62
15. Sherriff FE, Bridges LR, Gentleman SM, Sivaloganathan S, Wilson S. Markers of axonal injury in post mortem human brain. Acta Neuropathol 1994;88:433-39
16. Giometto B, An SF, Groves M, et al. Accumulation of β-amyloid precursor protein in HIV encephalitis: Relationship with neuropsychological abnormalities. Ann Neurol 1997;42:34-40
17. An SF, Ciardi A, Scaravilli F. PCR detection of HIV proviral DNA (gag) in the brains of patients with AIDS: Comparison between results using fresh frozen and paraffin wax-embedded specimens. J Clin Pathol 1994;47:990-94
18. An SF, Giometto B, Scaravilli F. HIV-1 DNA in brains in AIDS and pre-AIDS: Correlation with the stage of disease. Ann Neurol 1996;40:611-17
19. Kawarabayashi T, Shoji M, Harigaya Y, Yamaguchi H, Hirai S. Expression of APP in the early stage of brain damage. Brain Res 1991;563:334-38
20. Nakamura Y, Takeda M, Niigawa H, Hariguchi S, Nishimura T. Amyloid beta protein precursor deposition in rat hippocampus lesioned by ibotenic acid injection. Neurosci Lett 1992;136:95-98
21. Otsuka N, Tomonaga M, Ikeda K. Rapid appearance of beta-amyloid precursor protein immunoreactivity in damaged axons and reactive glial cells in rat brain following needle stab injury. Brain Res 1991;568:335-38
22. Cochran E, Bacci B, Chen Y, Patton A, Gambretti P, Autilio-Gambetti L. Amyloid precursor protein and ubiquitin immunoreactivity in dystrophic axons is not unique to Alzheimer's disease. Am J Pathol 1991;139:485-89
23. Ohgami T, Kitamoto T, Taseishi J. Alzheimer's amyloid precursor protein accumulates within axonal swelling in human brain lesions. Neurosci Lett 1992;136:75-78
24. Gentleman SM, Nash MJ, Sweeting CJ, Graham DI, Roberts GW. β-Amyloid precursor protein (βAPP) as a marker for axonal injury after head injury. Neurosci Lett 1993;160:139-44
25. Graham DI, Adams JH, Nicoll JAR, et al. The nature, distribution and causes of traumatic brain injury. Brain Pathol 1995;5:397-406
26. McKenzie KJ, McLellan DR, Gentleman SM, Maxwell WL, Gennarelli TA, Graham DI. Is beta-APP a marker of axonal damage in short-surviving head injury? Acta Neuropathol 1996;92(6): 608-13
27. Giangaspero F, Foschini MP. Diffuse axonal swellings in a case of acquired immunodeficiency syndrome. Arch Pathol Lab Med 1988; 112:1259-62
28. Pittaluga A, Pattarini R, Severi P, Raiteri M. Human brain N-methyl-D-asparate receptors regulating noradrenaline release are positively modulated by HIV-1 coat protein gp120. AIDS 1996; 10(5):463-68
29. Tenhula WN, Xu SZ, Madigan MC, Heller K, Freeman WR, Sadun AA. Morphometric comparisons of optic nerve axon loss in acquired immunodeficiency syndrome. Am J Ophthalmol 1992; 113(1):14-20
30. Buzy J, Brenneman DE, Pert CB, Martin A, Salazar A, Ruff MR. Potent gp120-like neurotoxic activity in the cerebrospinal fluid of HIV-infected individuals is blocked by peptide T. Brain Res 1992; 598(1-2):10-8
31. Chong WK, Sweeney B, Wilkinson ID, et al. Proton spectroscopy of the brain in HIV infection: Correlation with clinical immunological and MR imaging findings. Radiology 1993;43:509-15
32. Chong WK, Paley M, Wilkinson ID, Hall-Craggs MA, Miller R, Kendall BE. Localised cerebral proton magnetic resonance spectroscopy in HIV infection and AIDS. Am J Neuroradiol 1994;15: 21-25
33. Lipton SA. HIV-related neurotoxicity. Brain Pathol 1991;1:193-99
34. Brenneman DE, Westbrook GL, Fitzgerald SP, et al. Neuronal cell killing by the envelop protein of HIV and its prevention by vaso-active intestinal peptide. Nature 1988;335:639-42
35. Dreyer EB, Kaiser PK, Offermann JT, Lipton SA. HIV-1 coat protein neurotoxicity prevented bt calcium channel antagonists. Science 1990;248:364-67
36. Kaiser PK, Offerman JT, Lipton SA. Neuronal injury due to HIV-1 envelop protein is blocked by anti-gp120 antibodies but not by anti-CD4 antibodies. Neurology 1990;40:1757-61
37. Tyor WR, Glass JD, Griffin JW, et al. Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann Neurol 1992;31:349-60
38. Wilt SG, Milward E, Zhou JM, et al. In vitro evidence for a dual role of tumor necrosis factor-alpha in human immunodeficiency virus type 1 encephalopathy. Ann Neurol 1995;37:381-94
39. Brenneman DE, Hill JM. Gp120-induced retardation of behavioral development in neonatal rats: Prevention by peptide T. Soc Neurosci Abstr 1990;16:615
40. Pert CB, Mervis RR Hill JM, et al. Morphological and behavioral response to acute and subacute i.c.v. gp120 administration in the rat. Soc Neurosci Abstr 1989;15:1387
41. Panlilio LV, Hill JM, Brenneman DE. Gp120 and VIP receptor antagonists impair Morris water maze performance in rats. Soc Neurosci Abstr 1990;16:1330
42. Povlishock JT, Jenkins LW. Are the pathological changes evoked by traumatic brain injury immediate and irreversible? Brain Pathol 1995;5:415-26
43. Shohami E, Novikov M, Bass R, Yamin A, Gallily R. Closed head injury triggers early production of TNFα and IL-6 by brain tissue. J Cerebral Blood Flow Metabol 1994;14:615-19
44. Taupin V, Toulmond S, Serrano A, Benavides J, Zavala F. Increase in IL-6, IL-1 and TNF levels in rat brain following traumatic lesion. J Neuroimmunol 1993;42:177-86
45. Woodroofe MN, Sarna GS, Wadhwa M, et al. Detection of interleukin-1 and interleukin-6 in adult rat brain, following mechanical injury, by in vivo microdialysis: Evidence of a role for microglia in cytokine production. J Neuroimmunol 1991;33:227-36
46. Rothwell NJ, Relton JK. Involvement of interleukin-1 and lipocortin-1 in ischaemic brain damage. Cerebrovasc Brain Metab Rev 1993;5:178-98
47. Glass JD, Wesselingh SL, Seines OA, McArthur JC. Clinical-neuropathologic correlation in HIV-associated dementia. Neurology 1993;43:2230-37
48. Wesselingh SL, Power C, Glass JD, et al. Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann Neurol 1993;33:576-82
49. Pettus EH, Christman CW, Giebel ML, Povlishock JT. Traumatically induced altered membrane permeability: Its relationship to traumatically induced reactive axonal change. J Neurotrauma 1994; 11:507-22
50. Dixon CD, Lyeth BG, Povlishock JT, et al. A fluid percussion model of experimental brain injury in the rat. J Neurosurg 1987;67: 110-19
51. Jenkins LW, Lyeth BG, Lewelt W, et al. Combined pretrauma scopolamine and phencyclidine attenuate posttraumatic increased sensitibity to delayed secondary ischemia. J Neurotrauma 1988;5:275-87
52. Jenkins LW, Moszynski K, Lyeth BG, et al. Increased vulnerability of the mildly traumatized rat brain to cerebral ischemia: The use of controlled secondary ischemia as a research tool to identify common or different mechanisms contributing to mechanical and ischemic brain injury. Brain Res 1989;477:211-24
53. Hayes RL, Jenkins LW, Lyeth BG. Neuropharmacological mechanisms of traumatic brain injury: Acetylcholine and excitatory amino acids. J Neurotrauma 1991;8:s173-87
54. Vion-Dury J, Nicoli F, Salvan AM, Conforet-Goung S, Dhiver C, Cozzone PJ. Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonance spectroscopy. Lancet 1996;345:60-61
55. Wilkinson ID, Lunn S, Miszkiel KA, et al. Proton MRS and quantitative MRI assessment of the short term neurological response to anti-retroviral therapy in AIDS. J Neurol Neurosurg Psychiat 1997. Forthcoming.